Global Life Science Business Partnering (GLSBP) - August 2026

Highlights of Deals in August 2026:

Acquisitions:

  1. Kedaara Capital bets on India’s orthopaedic market with US$200 Million Tynor deal.
  2. Piramal Pharma completed the acquisition of an additional 40.67% stake in Hyderabad-based CDMO Yapan Bio for Rs. 76 crore (~US$8 Million), taking its holding to 74% and making Yapan Bio a subsidiary.
  3. Hearzap, backed by 360 ONE Asset Management, completed the acquisition of Amplifon India’s hearing healthcare business, expanding its network to 420 centres across India. (Value undisclosed.)
  4. Eli Lilly to acquire Merida Biosciences for up to US$2.875 Billion, adding a precision autoantibody-degradation platform for autoimmune and allergic disease.
  5. Jazz Pharmaceuticals to acquire Actio Biosciences for US$820 Million upfront plus up to US$500 Million in milestones (up to US$1.32 Billion), expanding its rare epilepsy portfolio.
  6. LEO Pharma acquired Tanabe Pharma’s dersimelagon in a US$435 Million deal — a Phase 3-complete, FDA-filed oral MC1R agonist for erythropoietic protoporphyria.
  7. BioMarin entered into a definitive agreement to acquire Dutch biotech Alesta Therapeutics for its lead clinical-stage asset ALE1. (Value undisclosed.)


    Licensing:

    1. Lupin’s subsidiary VISUfarma entered an exclusive licensing agreement with Visus Therapeutics (Tenpoint Therapeutics) for YUVEZZI™, a presbyopia eye drop, across the EU, UK, Switzerland, Norway and Iceland, together with a strategic investment in Visus. (Value undisclosed.)
    2. Mankind Pharma signed an exclusive in-licensing and marketing agreement with China’s Chongqing Chenan Biopharmaceutical to commercialise Insulin Degludec and Insulin Degludec + Aspart Combination in India. (Value undisclosed).
    3. Elephas Biosciences Corporation, a US-based company that has developed an innovative live tissue platform for immunotherapy response prediction, has announced an exclusive partnership with Chennai-based Neuberg Diagnostics, one of India's leading pathology and molecular diagnostics groups.
    4. Gland Pharma and Neuland Labs announce strategic collaboration for sterile API manufacturing.
    5. Genentech licensed Hanmi Pharm’s first-in-class obesity and Type 2 diabetes candidate HM17321 — US$190 Million upfront in a deal worth up to US$2.3 Billion.
    6. SK Biopharmaceuticals and Biohaven signed a strategic global licensing agreement for Biohaven’s Kv7 ion channel platform and lead epilepsy candidate opakalim, worth up to US$795 Million.
    7. Teva bid US$57.5 Million upfront for BioXcel Therapeutics’ at-home treatment for schizophrenia and bipolar agitation.

      Investments/Fund Raising:

      1. Tata Capital Healthcare Fund III invests US$30 Million in Tenet Diagnostics.
      2. Natco Pharma invested a further US$14 Million in US xenotransplantation company eGenesis, through its Canadian and South African subsidiaries, taking its total investment to US$22 Million.
      3. Ayati Devices raised Rs. 15 crore (~US$1.7 Million) in a pre-Series A round led by Inflexor Ventures.
      4. Genentech will invest US$750 Million in a new end-to-end injectable fill-finish manufacturing facility in Hillsboro, Oregon.
      5. Amylyx Pharmaceuticals priced a US$500.2 Million public offering to fund pre-commercial activity for its lead asset avexitide.
      6. Braveheart Bio priced a US$382.5 Million IPO to advance BHB-1893, a next-generation oral cardiac myosin inhibitor for hypertrophic cardiomyopathy.
      7. LifeMine Therapeutics raised US$263 Million (US$188 Million Series E and US$75 Million Series D) — the largest private round of the month — to advance LIFE-001 in transplantation and immunology.


      Aagami Updates:

      1. New Client Win: Aagami Appointed by Innovative Biopharmaceutical Company from Belgium to Secure commercialization partners in India for their CE-marked single-injection bioresorbable implant for Knee Osteoarthritis (OA)
      2. Akshay Bavaria, Associate Director attended Asia Bio Partnering 2026 (September 1–2 | Singapore) successfully with more than 30 one-to-one partnering meetings. 
      3. Aagami CEO Dinesh Jain, will be attending BioJapan 2026 (October 7–9 | Yokohama). Please send your meeting requests before the calendar fills up.
      4. Aagami team successfully attended Biotechgate Digital Partnering between Aug 31 – Sep 4, 2026.
      5. Aagami is pleased to announce affiliate partnership for Japan with Jun Tatsuno, M.S., R.Ph. 
        • With over 40 years of global pharmaceutical experience—including leadership roles as GMCO at Brio Pharma, Board Director at YL Biologics, and European R&D Head at Mitsubishi Tanabe—Jun brings deep, hands-on expertise in PMDA regulatory strategy, MAH establishment, and cross-border licensing. 
        • His addition significantly strengthens Aagami's on-the-ground execution and deal-making capabilities for our clients entering the Japanese and broader APAC life sciences markets.


        INFOCUS: Select opportunities available at Aagami:

        Market Stage Assets For Licensing/Partnering

        1. Licensing Available: FDA-Cleared Portable MRI & AI Guided Robotics Surgery Platform for Prostate Cancer. Applicable for other indications too. 290+ systems sold and $195M in cumulative orders to date across 32+ U.S. states & 19 countries.
        2. Seeking Partner / Distribution: CE-marked single-injection bioresorbable implant (KioMedine VSOne) for Knee Osteoarthritis (OA). Patented non-animal carboxymethyl-chitosan with unique ROS-scavenging action. One Injection. Delivers 9–12 months of pain relief; proven efficacy in HA/steroid-refractory patients. Marketed across 25 countries.
        3. First-in-class, broad-spectrum antimicrobial peptide (Peceleganan / PL-5) targeting bacterial & fungal cell membranes with low resistance potential. Market-approved in China for burn wound infections (Phase 3b complete) and Phase 2-ongoing in the US for Diabetic Foot Infections (DFI).
        4. Dental gel (Marketed in the US & approved in EU) for Prevention & Treatment of Periodontitis, Gingivitis, & Caries. Featured in WSJ, FOX, NBC, ABC, GQ. Already a profit making product. Licensing available. US$ 40.2M Sales in 2025 in USA. 
        5. High ROI Opportunity to Partner in another U.S. (California) based medtech revolutionizing medical imaging, diagnosis and robotic surgery for Brain and Head (US FDA cleared). Focus on Strokes and TBI. Secured $23M in sales contracts for 2025 and 2026. Currently raising a $30M Series B, of which $20M is already closed.


        [In-Development Stage]

        1. Phase 3 stage small molecule eye drop to treat Cataract (First in class). Brings paradigm shift in OPTH. Uses known molecule.
        2. Phase 3 stage Erythropoietin (EPO) asset for Resuscitation from Sudden Cardiac Arrest (A groundbreaking approach). Seeking strategic partner/investment, and EPO supplier also.
        3. Phase 2 Broad-Spectrum Revolutionary Antiviral (PRV Eligible). Includes the Coronavirus family, including SARS-CoV-2 (COVID, Long COVID), RSV, Influenza A (including H5N1 "Bird Flu"), as well as Smallpox/MPOX, Measles and Ebola.
        4. Available for Licensing/Co-development: Biosimilars such as Adalimumab, Rituximab, & Infliximab with ~2028-29 market launch timeline.
        5. Phase 3-Ready Biological Franchise for Smoking Cessation. 2 Injection dosing regimen with no side effect. Phase 2 completed.
        6. Seeking Licensing/Partnering: Biobetters Clinical-stage portfolio of 2nd & 3rd-gen therapeutic enzymes (Phase 1) engineered to address known immunogenicity and short half-life limitations. Targets include PKU, ALL/LBL, and ASS1-deficient solid tumors, featuring extended dosing intervals and strong safety profiles. Estimated market approval ~2029-2030
        7. Seeking Licensing/Partnering: Phase 3-Ready Drug safety-optimized to treat Atrial Fibrillation (AF);eliminates 3-day hospital onboarding for outpatient prescribing (dofetilide + mexiletine). FDA protocol reviewed, addressing 33M+ patients global market with >$1B peak sales potential.


        For Investment:

        1. High ROI Opportunity to Invest in U.S. based MedTech revolutionizing medical imaging with the world’s first portable, single-sided MRI platform for Prostate Cancer (On the market). Currently raising last round - Series C targeting up to $70M. Exit via an IPO, strategic M&A, or private equity buyout.
        2. Seeking Investment ($30–$40 Million Series A): High-ROI opportunity in Phase 3-ready cardiovascular drug targeting Atrial Fibrillation with >$1B peak annual sales potential. Funds will be used for Phase 3 clinical trials, CMC manufacturing readiness, and FDA NDA filing. Exit via Strategic M&A or IPO.
        3. Seeking Investment (US$ ~3.76 Million raised in 2026): Join Investors such as BIRAC in uncoupling Metastasis and Proliferation with translational platform, using Machine Learning and known molecules to disrupt cancer treatment. The funds will be used to progress the pipeline to the out-licensing stage.
        4. High ROI Opportunity to Invest in another U.S. (California) based medtech revolutionizing medical imaging for Brain and Head (US FDA cleared). Exit via an IPO, strategic M&A, or private equity buyout. Secured $23M in sales contracts for 2025 and 2026. Currently raising a $30M Series B, of which $20M is already closed.

        For Acquisition:

        1. [URGENT] Lucrative (Less than $300K) Opportunity to acquire IP Portfolio (bankruptcy disposition) of clinical stage First-in-Class Non-Opioid Analgesic. Few discussions already ongoing. 2 Bids under evaluation by Bankruptcy Trustee.
        2. Available at a very reasonable price - Mountain View Pharma (MVP) including its PharmaPEG® technologyfor Next-generation biologics, its product candidates, data package of ~20 drug candidates, IP, NOL and Federal benefits etc. 
        3. A High Multiple ROI by acquiring small molecule clinical asset in rare diseases (sickle cell disease & thalassemia). (Two Phase 1 completed. Phase 2 ready). Low cost and quicker to market vs. Gene Therapy. Their previous asset was acquired for US$400 million.


        Hope you found the content useful. We welcome your feedback and queries.